tiprankstipranks
Innate Pharma SA (IPHYF)
OTHER OTC:IPHYF
US Market

Innate Pharma SA (IPHYF) Income Statement

Compare
27 Followers

Innate Pharma SA Income Statement

Last quarter (Q2 2024), Innate Pharma SA's total revenue was €12.35M, a decrease of -38.58% from the same quarter last year. In Q2, Innate Pharma SA's net income was €-24.76M. See Innate Pharma SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
€ 51.90M€ 49.64M€ 12.11M€ 56.83M€ 68.97M
Gross Profit
€ -4.12M€ -2.02M€ -34.89M€ 53.79M€ 23.82M
Operating Expenses
€ 64.57M€ 66.06M€ 59.94M€ 75.38M€ 50.87M
Depreciation and Amortization
€ 5.09M€ 4.42M€ 4.57M€ 9.38M€ 16.53M
EBITDA
€ -7.58M€ -61.30M€ -43.23M€ 43.10M€ -20.86M
Operating Income
€ -12.67M€ -11.65M€ -47.83M€ -13.69M€ -27.05M
Other Income/Expenses
€ 5.10M€ -547.00K€ 2.35M€ -15.53M€ 6.29M
Pretax Income
€ -7.57M€ -57.97M€ -45.48M€ -63.98M€ -20.76M
Net Income
€ -7.57M€ -99.10M€ -59.14M€ -70.75M€ -20.96M
Per Share Metrics
€ ―€ ―€ ―€ ―€ ―
Basic EPS
€ -0.09€ -1.24€ -0.74€ -0.90€ -0.31
Diluted EPS
€ -0.09€ -1.24€ -0.74€ -0.90€ -0.31
Weighted Average Shares Outstanding
80.45M 79.64M 79.54M 78.93M 66.91M
Weighted Average Shares Outstanding (Diluted)
80.45M 79.64M 79.54M 78.93M 66.91M
Currency in EUR

Innate Pharma SA Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis